Helping pharma to develop safer drugs faster

Dundee Cell Proteomics TargetIdTM

DCP TargetId technology uses quantitative proteomics to determine drug mechanism, identify drug targets in the cell and analyse the cellular proteome expression and localisation profile following treatment with a drug.

The process of target identification and validation usually involves a variety of scientific activities focused on identifying new drug targets and confirming their role in disease. However, recently as more and more information on the mode of action of drugs has become available, targeting cellular pathways of proteins rather than individual proteins is likely to lead to the development of better and safer drugs.

TargetId provides a new tool to elucidate cellular pathways affected by drugs. Information on drug interactions with cellular pathways is important in determining selectivity and off-target effects.

The process involves the following steps:

  • Identify cell line or tissue for analysis
  • Proteome-wide scanning for interacting partners to drugs
  • Identify new drug targets
  • Evaluate drug specificity in cellular environment

This technology provides information on proteome-wide interactions between a drug and cellular proteins and allows for the ranking of low and high affinity binders as well as elucidation of biochemical pathways affected by exposure of the cell or tissue to the compound.

TargetId combines an unparalleled multidisciplinary workflow, expertise in high-resolution quantitative mass spectrometry, biochemistry, cell biology, chemical biology and bioinformatics to deliver a comprehensive analysis of a compound’s interactions with cellular proteins.

Major applications of the technology include:

  • Target identification from phenotypic screening assays
  • Drug lead optimization
  • Clinical candidate selection
  • Drug mechanism and pathway identification
  • Drug reprofiling: profiling proteins of the cellular proteome that interact with a drug is important in obtaining information for repositioning the drug by developing novel indications for the compound.

 

Outline of Process for Cellular Target Identification